Stockscreener 앱 받기
1.46
5.04%
0.07
시간 외 거래:
1.48
0.02
+1.37%
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd gives 17 new hires options to buy 731,000 shares - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com India
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com
Invivyd Ends King & Spalding Lobbying Engagement After Three Weeks - Legis1
Invivyd (IVVD) price target increased by 25.00% to 10.20 - MSN
Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
IVVD Price Today: Invivyd, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Biotech Biz Moves Into Ex-Bank Site - New Haven Independent
Invivyd Shareholder Action Reminder - TMX Newsfile
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Invivyd, Inc. draws on 73 years of DNA innovation to guide viral research - Traders Union
Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
Is Invivyd (IVVD) stock overvalued today | Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Analyst Ratings - Cổng thông tin điện tử tỉnh Lào Cai
Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Real Time Stock Idea Network - Xã Châu Thành
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody strategy strong enough for COVID market - AD HOC NEWS
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - The Manila Times
Invivyd chair joins Mehmet Oz, Mark Cuban at POLITICO health event - Stock Titan
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody edge strong enough for COVID market rec - AD HOC NEWS
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
1.77%
0.25%
자본화:
|
볼륨(24시간):